116 - The Rising Threat of Dengue and Other Arboviruses

Friday, October 18, 2024

10:30 AM – 11:45 AM US PT

Location: Concourse 152

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Costi Sifri, MD (he/him/his)

Professor, Director of Hospital Epidemiology
University of Virginia School of Medicine
Charlottesville, VA, United States
Angela Campbell, MD, MPH

Medical Officer
Coronavirus and Other Respiratory Viruses Division
Centers for Disease Control and Prevention
Atlanta, GA, United States

Faculty(s)

Alfonso Hernandez-Romieu, MD, MPH (he/him/his)

Medical Officer
CDC
Atlanta , GA, United States
Carina Blackmore, DVM, PhD, Dipl ACVPM (09), CPM (she/her/hers)

State Epidemiologist, Director, Division of Disease Control and Health Protection
Florida Department of Health
Tallahassee, FL, FL, United States
Albert Ko, MD (he/him/his)

Professor
Department of Epidemiology of Microbial Diseases
Yale School of Public Health/Oswaldo Cruz Foundation/Brazilian Ministry of Health
New Haven, Connecticut, United States

Disclosure(s):

Costi Sifri: No financial relationships to disclose

Angela P. Campbell, MD, MPH: No financial relationships to disclose

Alfonso C. Hernandez-Romieu, MD, MPH: No financial relationships to disclose

Carina Blackmore, DVM, PhD, Dipl ACVPM (09), CPM: No financial relationships to disclose

Albert I. Ko, MD: Merck and Company, Inc.: Member, Scientific Advisory Committee, Dengue Vaccine Program (Ongoing); Takeda Vaccines: Grant/Research Support (Ongoing); Valneva Austria GmbH: Grant/Research Support (Ongoing)

Learning Objectives:

At the conclusion of this session, participants will be able to:

analyze the evolving epidemiology of dengue virus infection, identify its clinical manifestations, and discuss management strategies;
Identify the immunological responses to dengue virus, offer insights into vaccine development, and discuss novel approaches to vector control;
describe public health approaches to preparedness and response to emerging arboviral outbreaks including dengue virus and oropouche virus.

Presentations:

10:30 AM – 10:55 AM US PT

Current Epidemiology and Clinical Considerations of Dengue
Speaker: Alfonso C. Hernandez-Romieu, MD, MPH (he/him/his) – CDC
10:55 AM – 11:20 AM US PT

Advances in Dengue Prevention: New Insights and Challenges for Vaccination and Vector Control
Speaker: Albert I. Ko, MD (he/him/his) – Yale School of Public Health/Oswaldo Cruz Foundation/Brazilian Ministry of Health
11:20 AM – 11:45 AM US PT

Preparing for Emerging Arboviral Threats at the Frontlines: The Response to Dengue and Oropouche in Florida
Speaker: Carina Blackmore, DVM, PhD, Dipl ACVPM (09), CPM (she/her/hers) – Florida Department of Health